See more : GAME HOURS Inc. (6626.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of X4 Pharmaceuticals, Inc. (XFOR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of X4 Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Shenzhen Investment Limited (0604.HK) Income Statement Analysis – Financial Results
- Alpha Tau Medical Ltd. (DRTSW) Income Statement Analysis – Financial Results
- Shanghai Sinyang Semiconductor Materials Co., Ltd. (300236.SZ) Income Statement Analysis – Financial Results
- Advance Energy Plc (ADV.L) Income Statement Analysis – Financial Results
- Syrah Resources Limited (SYR.AX) Income Statement Analysis – Financial Results
X4 Pharmaceuticals, Inc. (XFOR)
About X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 3.00M | 0.00 | 3.50M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.00M | 1.99M | 1.89M | 0.00 | 672.00K | 103.00K | 195.00K | 300.00K | 400.00K |
| Gross Profit | -2.00M | -1.99M | -1.89M | 3.00M | -672.00K | 3.40M | -195.00K | -300.00K | -400.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 97.06% | 0.00% | 0.00% | 0.00% |
| Research & Development | 72.02M | 61.06M | 50.65M | 41.93M | 30.16M | 30.98M | 28.13M | 17.83M | 12.71M |
| General & Administrative | 0.00 | 0.00 | 24.70M | 20.94M | 17.64M | 18.41M | 8.01M | 6.52M | 2.12M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 35.51M | 27.02M | 24.70M | 20.94M | 17.64M | 18.41M | 8.01M | 6.52M | 2.12M |
| Other Expenses | 0.00 | -6.27M | -3.57M | -2.11M | -1.10M | -85.00K | -16.00K | 104.00K | -77.00K |
| Operating Expenses | 107.52M | 88.08M | 75.35M | 62.87M | 47.80M | 46.21M | 32.27M | 21.96M | 12.67M |
| Cost & Expenses | 107.52M | 88.08M | 75.35M | 62.87M | 47.80M | 46.21M | 32.27M | 21.96M | 12.67M |
| Interest Income | 4.58M | 219.00K | 10.00K | 273.00K | 1.20M | 809.00K | 214.00K | 0.00 | 0.00 |
| Interest Expense | 5.78M | 3.99M | 3.64M | 2.69M | 2.15M | 1.04M | 2.08M | 2.52M | 472.00K |
| Depreciation & Amortization | 419.00K | 1.99M | 1.89M | 1.23M | 672.00K | 103.00K | 195.00K | 300.00K | 389.00K |
| EBITDA | -107.52M | -87.57M | -85.11M | -58.07M | -51.70M | -45.89M | -31.60M | -20.16M | -12.35M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -1,995.80% | 0.00% | -1,195.06% | 0.00% | 0.00% | 0.00% |
| Operating Income | -107.52M | -87.57M | -85.11M | -59.87M | -51.70M | -45.89M | -36.13M | -24.35M | -14.83M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -1,995.80% | 0.00% | -1,311.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 6.43M | -6.27M | -3.57M | -2.11M | -1.10M | 2.86M | 2.26M | 6.48M | 1.61M |
| Income Before Tax | -101.09M | -93.84M | -88.68M | -61.98M | -52.81M | -43.02M | -33.88M | -22.98M | -13.22M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -2,066.10% | 0.00% | -1,229.17% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 78.00K | 28.00K | 17.00K | 148.00K | 3.80M | 3.90M | 1.87M | 2.62M | 395.00K |
| Net Income | -101.17M | -93.87M | -88.70M | -62.13M | -56.60M | -43.02M | -33.88M | -22.98M | -13.22M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -2,071.03% | 0.00% | -1,229.17% | 0.00% | 0.00% | 0.00% |
| EPS | -0.57 | -1.48 | -3.44 | -3.09 | -4.91 | -93.73 | -98.58 | -24.76 | -14.24 |
| EPS Diluted | -0.57 | -1.48 | -3.44 | -3.09 | -4.91 | -93.73 | -98.58 | -24.76 | -14.24 |
| Weighted Avg Shares Out | 177.81M | 63.53M | 25.75M | 20.08M | 11.53M | 459.00K | 343.64K | 928.01K | 928.01K |
| Weighted Avg Shares Out (Dil) | 177.81M | 63.53M | 25.75M | 20.08M | 11.53M | 459.00K | 343.64K | 928.01K | 928.01K |
X4 Pharmaceuticals to Present at April Investor Conferences
X4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q4 2021 Results - Earnings Call Transcript
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
X4 Pharmaceuticals to Announce Fourth Quarter 2021 Financial Results and Host a Conference Call and Webcast on March 17, 2022
X4 Pharmaceuticals to Present at March Investor Conferences
X4 Pharmaceuticals to Present at B. Riley Securities Oncology Investor Conference
Low Float Penny Stocks To Watch After SOPA Stock Explodes
These Biotech Penny Stocks Exploded Today, Here's Why
Why Did X4 Pharmaceuticals Shares Crater To 52-Week Low?
X4 Pharmaceuticals Presents New Clinical and Scientific Data at 2021 ASH Annual Meeting Supporting Broader Potential for Mavorixafor in the Treatment of Primary Immunodeficiencies
Source: https://incomestatements.info
Category: Stock Reports
What is the projected cash runway for X4 Pharmaceuticals?
X4 Pharmaceuticals Inc (NASDAQ:XFOR) ended the third quarter of 2024 with cash and equivalents of almost $136 million, providing a financial runway into late 2025.
What were X4 Pharmaceuticals’ net revenues in Q3 2024?
Revenue and Cost of Revenue: For the three months ended September 30, 2024 , X4 reported net product revenue of $0.6 million and cost of revenue of $0.2 million related to the sale of XOLREMDI.